论文部分内容阅读
目的比较多西他赛+表柔比星+环磷酰胺(TEC方案)与多西他赛+表柔比星(TE方案)新辅助化疗方案治疗绝经前乳腺癌的临床疗效和不良反应。方法选择2009年1月至2013年12月间廉江市人民医院收治的72例绝经前乳腺癌患者,按照随机数字表法随机分为观察组36例和对照组36例,观察组患者给予TEC方案治疗,对照组患者给予TE方案治疗。对两组患者治疗后的近期临床疗效及不良反应进行比较。结果观察组与对照组患者的总有效率、病理完全缓解率相比较,差异无统计学意义(P>0.05)。观察组患者的中性粒细胞减少及血小板减少的发生率明显高于对照组患者,差异有统计学意义(P<0.05)。两组患者的恶心呕吐、肝功能异常、心脏毒性及脱发的发生率相比较,差异无统计学意义(P>0.05)。结论在绝经前乳腺癌治疗中,TEC与TE新辅助化疗方案的近期临床疗效相似,而TE方案的不良反应发生率低,值得临床推广与应用。
Objective To compare the clinical efficacy and side effects of neoadjuvant chemotherapy with docetaxel + epirubicin + cyclophosphamide (TEC) and docetaxel + epirubicin (TE) in the treatment of premenopausal women with breast cancer. Methods Seventy-two patients with premenopausal breast cancer who were treated in Lianjiang People’s Hospital from January 2009 to December 2013 were randomly divided into observation group (36 cases) and control group (36 cases) according to random number table method. Patients in observation group were given TEC Program treatment, control group patients given TE program treatment. The two groups of patients after treatment of recent clinical efficacy and adverse reactions were compared. Results There was no significant difference between the total effective rate and complete remission rate in observation group and control group (P> 0.05). The incidence of neutropenia and thrombocytopenia in the observation group was significantly higher than that in the control group (P <0.05). There was no significant difference between the two groups in nausea and vomiting, liver dysfunction, cardiotoxicity and the incidence of hair loss (P> 0.05). Conclusions In the treatment of premenopausal breast cancer, the recent clinical efficacy of TEC and TE neoadjuvant chemotherapy is similar, but the adverse reaction rate of TE is low, which is worthy of clinical application and promotion.